BIO-key Seeks Shareholder Approval for 53% Dilutive Warrant Issuance
BKYI is trading near its 52-week low of $2.96 (7.4% above the low).
Summary
BIO-key filed a preliminary proxy supplement adding a shareholder vote on issuing up to 1,236,668 shares upon exercise of new warrants from an August 10 warrant inducement transaction, which could dilute existing shareholders by approximately 53.2%.
Key Events · Financing and Capital Events · BKYI
-
Warrant Inducement Transaction
On August 10, 2026, BIO-key entered into an agreement with Armistice Capital to exercise existing warrants for 618,334 shares at a reduced price of $4.06, generating $2.5 million in gross proceeds.
-
New Warrants and Dilution
In exchange, the company issued new warrants to purchase up to 1,236,668 shares at $4.06 per share, representing 200% warrant coverage. Full exercise would dilute existing shareholders by approximately 53.2%.
-
Shareholder Vote Required
The new warrants are not exercisable until shareholders approve the issuance at the September 3 annual meeting. If approved, the company could receive an additional $5.0 million in gross proceeds.
-
Nasdaq Compliance
The shareholder vote is required under Nasdaq Listing Rule 5635(d) because the new warrant issuance exceeds 20% of outstanding shares at a price below the minimum price.
Analysis · BKYI · Technology
BIO-key is asking shareholders to approve the issuance of up to 1,236,668 shares upon exercise of new warrants issued in an August 10 warrant inducement transaction. If approved and fully exercised, existing shareholders would face approximately 53.2% dilution. The company received $2.5 million from the existing warrant exercise and could receive an additional $5.0 million if the new warrants are exercised. This is a significant financing event for a company with a market cap of only $3.5 million and a going concern warning.
At the time of this filing, BKYI was trading at $3.18 on NASDAQ in the Technology sector, with a market capitalization of approximately $3.5M. The 52-week trading range was $2.96 to $19.70. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.